It Should Not Be This Difficult to Engage Pharma in an Effective, Safe, Inexpensive Product for Acute Migraine, the Third Most Prevalent Disease in the World.
作者信息
Hagan John C
机构信息
Kansas City, Missouri, ophthalmologist and Missouri Medicine Editor since 2000. He is a multi-year Diamond Contributor to MMPAC.
出版信息
Mo Med. 2022 Jan-Feb;119(1):4-6.
Abstract
摘要
相似文献
1
2
Role of magnesium in the pathogenesis and treatment of migraine.
Expert Rev Neurother. 2009 Mar;9(3):369-79. doi: 10.1586/14737175.9.3.369.
3
Galcanezumab effect on "whole pain burden" and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience.
J Headache Pain. 2022 Jun 13;23(1):69. doi: 10.1186/s10194-022-01436-6.
4
Pharmacological synergy: the next frontier on therapeutic advancement for migraine.
Headache. 2012 Apr;52(4):636-47. doi: 10.1111/j.1526-4610.2011.02058.x. Epub 2012 Jan 6.
5
Why all migraine patients should be treated with magnesium.
J Neural Transm (Vienna). 2012 May;119(5):575-9. doi: 10.1007/s00702-012-0790-2. Epub 2012 Mar 18.
6
A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment.
Headache. 2020 Jul;60(7):1325-1339. doi: 10.1111/head.13835. Epub 2020 Jun 8.
7
[Argentinean consensus guidelines on the use of monoclonal antibodies in patients with migraine].
Rev Neurol. 2020 Feb 16;70(4):149-158. doi: 10.33588/rn.7004.2019399.
8
Cost considerations in headache treatment. Part 2: Acute migraine treatment.
Headache. 1996 Sep;36(8):493-502. doi: 10.1046/j.1526-4610.1996.3608493.x.
9
The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability.
Pharmacogenet Genomics. 2009 Jun;19(6):422-8. doi: 10.1097/FPC.0b013e32832af5a3.
10
Medications Approved for Preventing Migraine Headaches.
Am J Med. 2020 Jun;133(6):664-667. doi: 10.1016/j.amjmed.2020.01.031. Epub 2020 Mar 5.
引用本文的文献
1
Mixing It Up: The Art and Science of Compounding Pharmacy.
Mo Med. 2025 Mar-Apr;122(2):76-80.
2
Timolol 0.5% Eye Drops for Essential Tremor: First Successful Case Report.
Mo Med. 2024 Nov-Dec;121(6):464-466.
3
Nasally Delivered 0.5% Timolol Beta Blocker Successfully Treats Acute Migraines in a Referral Headache Clinic: A Case Series.
Mo Med. 2024 Jan-Feb;121(1):33-36.
本文引用的文献
1
Short-term Efficacy and Safety of Topical β-Blockers (Timolol Maleate Ophthalmic Solution, 0.5%) in Acute Migraine: A Randomized Crossover Trial.
JAMA Ophthalmol. 2020 Nov 1;138(11):1160-1166. doi: 10.1001/jamaophthalmol.2020.3676.
2
Put a Drop of Timolol Into Each Eye and Call Me in the Morning.
JAMA Ophthalmol. 2020 Nov 1;138(11):1166-1167. doi: 10.1001/jamaophthalmol.2020.3837.
3
Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality.
Int J Pharm Compd. 2020 May-Jun;24(3):194-197.
4
A Randomized, Double-Blinded, Placebo-Controlled, Cross Over Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine.
Kans J Med. 2020 Feb 26;13(Suppl 2):2-5. eCollection 2020.
5
Beta Blocker Eye Drops Have Dramatically Helped My Severe Migraines.
Mo Med. 2018 Nov-Dec;115(6):525.
6
Topical Beta Blockers for the Treatment of Acute Migraines in 2019.
Mo Med. 2018 Nov-Dec;115(6):522-524.
7
Answering the Call: A Prospective Look at the Role of Timolol Eye Drops in the Treatment of Acute Migraine Attacks.
Mo Med. 2018 Nov-Dec;115(6):520-521.
8
Timolol Eyedrops in the Treatment of Acute Migraine Attacks: A Randomized Crossover Study.
JAMA Neurol. 2018 Aug 1;75(8):1024-1025. doi: 10.1001/jamaneurol.2018.0970.
9
Can topical beta blockers be successful for acute migraine management?
Mo Med. 2014 Jul-Aug;111(4):294-6.
10
Ophthalmic beta blockers: treatment for acute migraine?
Mo Med. 2014 Jul-Aug;111(4):292-3.
Zotero 插件